Pitavastatin enhances the anti-fibrogenesis effects of candesartan, an angiotensin II receptor blocker, on CCl4-induced liver fibrosis in rats

Journal of UOEH

Volumn 26, Issue 2, 2004, Pages 165-177

  Nie, Lianbo ^a   Imamura, Michio ^a   Itoh, Hideaki ^a   Ueno, Hikaru ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Angiotensin II; Candesartan; Liver fibrogenesis; Pitavastatin; TGF

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CARBON TETRACHLORIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYPROLINE; PITAVASTATIN; PLACEBO; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FIBROGENESIS; HISTOPATHOLOGY; KIDNEY INJURY; LIVER FIBROSIS; LIVER INJURY; MALE; MOLECULAR MECHANICS; NONHUMAN; PROTEIN EXPRESSION; RAT; STAINING; STATISTICAL SIGNIFICANCE;

EID: 3042791446     PISSN: 0387821X     EISSN: None     Source Type: Journal    
DOI: 10.7888/juoeh.26.165     Document Type: Article

References (30)

1. Border WA & Noble N (2001): Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases. Semin Nephrol 21: 563-572
2. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H & Fukui H (2001): Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34: 745-750
3. Schneider AW, Kalk JF & Klein CP (1999): Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 29: 334-339
4. Tuncer I, Ozbek H, Ugras S & Bayram I (2003): Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. Exp Toxicol Pathol 55: 159-166
5. Moriyama T, Kawada N, Nagatoya K, Takeji M, Horio M, Ando A, Imai E & Hori M (2001): Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int 59: 2095-2103
6. Park JK, Muller DN, Mervaala EM et al (2000): Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 58: 1420-1430
7. Ichiki T, Takeda K, Tokunou T, Iino N, Egashira K, Shimokawa H, Hirano K, Kanaide H & Takeshita A (2001): Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21: 1896-1901
8. Akeba T, Shibuta T, Amano Y et al (1998): Six-month repeated oral toxicity study of NK-104 in rats. J Toxicol Sci 23: 713-720
9. Akeba T, Shibuta T, Amano Y, Okubo M, Asanuma A, Koga T, Tanaka M & Takimoto M (1998): 28-day repeated oral toxicity study of a hypolipidemic agent, NK-104 in rats. J Toxicol Sci 23: 701-711
10. Woessner JJ (1961): The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 93: 440-447
11. Harrison-Bernard LM, El-Dahr SS, O'Leary DF & Navar LG (1999): Regulation of angiotensin II type 1 receptor mRNA and protein in angiotensin II-induced hypertension. Hypertension 33: 340-346
12. Hautekeete ML & Geerts A (1997): The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch 430: 195-207
13. Gressner AM (1996): Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Kidney Int Suppl 54: S39-S45
14. Gaillard-Sanchez I, Bruneval P, Clauser E, Belair MF, Da Silva JL, Bariety J, Camilleri JP & Corvol P (1990): Successful detection by in situ cDNA hybridization of three members of the serpin family: angiotensinogen, alpha 1 protease inhibitor, and antithrombin III in human hepatocytes. Mod Pathol 3: 216-222
15. Kon Y, Endoh D, Yamashita T & Watanabe T (1998): Expression of renin in the rat liver. Anat Histol Embryol 27: 111-118
16. Yokota S, Tsuji H & Kato K (1985): Localization of cathepsin D in rat liver. Immunocytochemical study using post-embedding immunoenzyme and protein A-gold techniques. Histochemistry 82: 141-148
17. Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V & Rodes J (2000): Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118: 1149-1156
18. Bataller R, Sancho-Bru P, Gines P et al (2003): Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 125: 117-125
19. Rombouts K, Kisanga E, Hellemans K, Wielant A, Schuppan D & Geerts A (2003): Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol 38: 564-572
20. Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H & Iwai M (2003): Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 107: 106-112
21. Yoshiji H, Kuriyama S & Fukui H (2002): Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 23: 348-356
22. Rosmorduc O, Wendum D, Corpechot C, Galy B, Sebbagh N, Raleigh J, Housset C & Poupon R (1999): Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Pathol 155: 1065-1073
23. Yoshiji H, Kuriyama S, Yoshii J et al (2003): Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 52: 1347-1354
24. Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, Housset C & Rosmorduc O (2002): Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 35: 1010-1021
25. Chua CC, Hamdy RC & Chua BH (1998): Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1401: 187-194
26. Weis M, Heeschen C, Glassford AJ & Cooke JP (2002): Statins have biphasic effects on angiogenesis. Circulation 105: 739-745
27. Noble NA & Border WA (1997): Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target? Semin Nephrol 17: 455-466
28. Qi Z, Atsuchi N, Ooshima A, Takeshita A & Ueno H (1999): Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci 96: 2345-2349
29. Ueno H, Sakamoto T, Nakamura T, Qi Z, Astuchi N, Takeshita A, Shimizu K & Ohashi HA (2000): Soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. Hum Gene Ther 11: 33-42
30. Nakamura T, Sakata R, Ueno T, Sata M & Ueno H(2000): Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 32: 247-255